"VIPREG2024 1xbet sign up promo code Komors"

Highly effective prophylactic vaccines are available for two of the most important cancer-causing infections, hepatitis B virus (HBV) and human papillomavirus (HPV) (see Infection). In 2022, there were an estimated 254 million people globally with chronic HBV infection; HBV infection causes nearly one million deaths annually, mostly from cirrhosis and1

Modifiable risk factors cause a large proportion of cancer cases and deaths. A recent study shows that an estimated 40% of all cancer cases and 44% of cancer deaths in the United States are attributable to a combination of modifiable risk factors, including tobacco use, excess body fatness, and alcohol1

Excess body fatness – overweight and obesity – has been linked to at least 13 types of cancer. Overall, approximately 4.5% of all cancer deaths globally are attributable to excess body fatness, varying from <1% in low-income countries to 7-8% in some high-income countries. The proportion of deaths linked to1

At the American Cancer Society, we often celebrate the extraordinary progress we have made to reduce the death and suffering from cancer, driven by dramatic changes in the use of combustible tobacco, strategies to detect cancer earlier, the explosion of new therapeutics, and a greater focus on survivorship. In fact,1

Cancer is now a major public health problem in sub-Saharan Africa, with the disease among the three leading causes of premature death (ages 30-69) in almost all countries in the region. About 820,000 new cancer cases and 550,000 deaths were estimated to have occurred in 2022 in sub-Saharan Africa. For1

Each country has opportunities to prevent and control cancer through resource-stratified evidence-based interventions across the entire cancer care continuum, from risk factor prevention, early detection and timely diagnosis, to quality treatment, survivorship, palliative care, and end-of-life care (Figure 32.1).

Cancer survival statistics highlight the degree of health care equity, reflecting the effectiveness of health systems in detecting, diagnosing, and treating cancers. Despite advancements in diagnostics and treatment, substantial disparities persist in international cancer survival both between and within countries due to inequality in the dissemination of advancements in diagnostic1

Global collaborative partnerships accelerate efforts to bridge the research gap, particularly in the areas of prevention and implementation and knowledge translation, to improve cancer outcomes worldwide. Countries and world regions need cancer research tailored to their unique disease burden and knowledge gaps to improve population health. Knowledge created in cancer1

Curbing the tobacco epidemic is a global health priority to reduce the burden of cancer and other chronic diseases. The World Health Organization Framework Convention on Tobacco Control, the first global public health treaty, entered into force in 2005 and developed a set of six key tobacco-control measures (MPOWER, Map1